Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Исследование ASP546C у взрослых с гастроэзофагеальным раком, раком поджелудочной железы или другими солидными опухолями

12 ноября 2026 г. обновлено: Astellas Pharma Global Development, Inc.

Фаза 1b/2 открытого исследования по оценке безопасности и эффективности ASP546C у участников с местно-распространенным неоперабельным или метастатическим гастроэзофагеальным аденокарциномом, аденокарциномой поджелудочной железы или другими типами солидных опухолей, экспрессирующих CLDN18.2

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach.

This study is in 2 parts. In both parts of the study, ASP546C will be given once in 3-week cycles. It will be given slowly through a tube into a vein. This is called an infusion.

In Part 1, people with gastric cancer or GEJ cancer can take part. They will receive an infusion of either a higher dose or a lower dose of ASP546C.

In Part 2, people with pancreatic cancer or who have one of the other solid tumors can take part. Part 2 doesn't include people with gastric cancer or GEJ cancer. All people in this part of the study will receive an infusion of the higher dose of ASP546C.

People will visit the clinic on certain days to receive ASP546C and have health checks. The number of visits and checks done during the study will depend on the health of each person and whether they are still receiving infusions of ASP546C.

Обзор исследования

Статус

Рекрутинг

Условия

Вмешательство/лечение

Тип исследования

Интервенционный

Регистрация (Оцененный)

150

Фаза

  • Фаза 2
  • Фаза 1

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

Места учебы

    • Alabama
      • Birmingham, Alabama, Соединенные Штаты, 35249
        • Рекрутинг
        • UAB Medicine - UAB Hospital
    • California
      • Los Angeles, California, Соединенные Штаты, 90025
        • Рекрутинг
        • START Los Angeles
      • Orange, California, Соединенные Штаты, 92868
        • Рекрутинг
        • UC Irvine Health-Chao Family Comprehensive Cancer Center
    • Florida
      • Miami, Florida, Соединенные Штаты, 33176
        • Рекрутинг
        • Miami Cancer Institute
    • Georgia
      • Atlanta, Georgia, Соединенные Штаты, 30322
        • Рекрутинг
        • Winship Cancer Institute at Emory University
    • Indiana
      • Indianapolis, Indiana, Соединенные Штаты, 46202
        • Рекрутинг
        • Indiana University (IU) Health - Multi-D Oncology Clinic
    • Michigan
      • Detroit, Michigan, Соединенные Штаты, 48201
        • Рекрутинг
        • Barbara Ann Karmanos Cancer Center
      • Grand Rapids, Michigan, Соединенные Штаты, 49546
        • Рекрутинг
        • START Midwest
    • Minnesota
      • Saint Louis Park, Minnesota, Соединенные Штаты, 55426
        • Рекрутинг
        • Health Partners Frauenshuh Cancer Center
    • New Hampshire
      • Lebanon, New Hampshire, Соединенные Штаты, 03756
        • Рекрутинг
        • Dartmouth-Hitchcock Medical Center
    • New Jersey
      • Basking Ridge, New Jersey, Соединенные Штаты, 07920
        • Рекрутинг
        • Memorial Sloan Kettering Basking Ridge
      • Hackensack, New Jersey, Соединенные Штаты, 07601
        • Рекрутинг
        • Hackensack University Medical Center
      • Middletown, New Jersey, Соединенные Штаты, 07748
        • Рекрутинг
        • Memorial Sloan Kettering Cancer Center Monmouth
      • Montvale, New Jersey, Соединенные Штаты, 07645
        • Рекрутинг
        • Memorial Sloan Kettering Bergen
      • New Brunswick, New Jersey, Соединенные Штаты, 08903
        • Рекрутинг
        • Rutgers Cancer Institute of New Jersey
    • New York
      • Commack, New York, Соединенные Штаты, 11725
        • Рекрутинг
        • Memorial Sloan Kettering Commack
      • Harrison, New York, Соединенные Штаты, 10604
        • Рекрутинг
        • Memorial Sloan Kettering Westchester
      • Lake Success, New York, Соединенные Штаты, 10042
        • Рекрутинг
        • START New York
      • Long Island City, New York, Соединенные Штаты, 11101
        • Рекрутинг
        • Memorial Sloan Kettering Cancer Center
      • Uniondale, New York, Соединенные Штаты, 11553
        • Рекрутинг
        • Memorial Sloan Kettering Nassau
    • North Carolina
      • Durham, North Carolina, Соединенные Штаты, 27710
        • Рекрутинг
        • Duke Cancer Center Durham
    • Oklahoma
      • Oklahoma City, Oklahoma, Соединенные Штаты, 73120
        • Рекрутинг
        • Mercy Coletta Cancer Center
    • Texas
      • Austin, Texas, Соединенные Штаты, 78758
        • Рекрутинг
        • Next Oncology - Austin
      • Houston, Texas, Соединенные Штаты, 77054
        • Рекрутинг
        • Next Oncology - Houston
      • Irving, Texas, Соединенные Штаты, 75039
        • Рекрутинг
        • Next Oncology - Dallas
      • San Antonio, Texas, Соединенные Штаты, 78229
        • Рекрутинг
        • START San Antonio (STSA)
    • Utah
      • Salt Lake City, Utah, Соединенные Штаты, 84112
        • Рекрутинг
        • Huntsman Cancer Institute University of Utah
      • West Valley City, Utah, Соединенные Штаты, 84119
        • Рекрутинг
        • START Mountain Region
    • Virginia
      • Fairfax, Virginia, Соединенные Штаты, 22031
        • Рекрутинг
        • Inova Schar Cancer Institute Clinical Trials
    • Washington
      • Seattle, Washington, Соединенные Штаты, 98101
        • Рекрутинг
        • Virginia Mason Medical Center
    • Wisconsin
      • Madison, Wisconsin, Соединенные Штаты, 53792
        • Рекрутинг
        • UW Health Carbone Cancer Center
    • Chiba
      • Kashiwa-shi, Chiba, Япония
        • Рекрутинг
        • National Cancer Center Hospital East
    • Tokyo
      • Chuo-ku, Tokyo, Япония
        • Рекрутинг
        • National Cancer Center Hospital
      • Koto-ku, Tokyo, Япония
        • Рекрутинг
        • The Cancer Institute Hospital of JFCR

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • Participant has a histologically confirmed diagnosis of gastroesophageal (gastric/GEJ/esophageal) adenocarcinoma, pancreatic adenocarcinoma, or pan-tumor (cholangiocarcinoma, colorectal adenocarcinoma, NSCLC [adenocarcinoma], SCLC, ovarian mucinous carcinoma or invasive breast cancer [ER/PR+HER2-; ER/PR-HER2+; ER/PR+HER2+ (triple positive); ER/PR-HER2- (triple negative)].

  • Participant has radiologically confirmed uLA/m gastroesophageal (gastric/GEJ/esophageal) adenocarcinoma, pancreatic adenocarcinoma or pan-tumor within 28 days prior to the first dose of study intervention.

  • Cohorts 1 to 3 only: Participant has measurable disease according to RECIST v1.1 within 28 days prior to the first dose of study intervention. For participants with only 1 measurable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy.

  • Cohort 4 only: Participant has radiologically evaluable disease (measurable and/or non-measurable) according to RECIST v1.1, within 28 days prior to the first dose of study intervention. For participants with only 1 evaluable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy.

  • Participant's tumor expresses CLDN18.2.

  • Participant has received at least 1 line of therapy for uLA/m disease.

  • Participant has an ECOG performance status of 0 or 1.

  • Participant has a predicted life expectancy >= 12 weeks.

  • Female participant is not pregnant and at least 1 of the following conditions apply:

    • Not a women of childbearing potential (WOCBP)
    • WOCBP who has a negative urine or serum pregnancy test at screening (Specific to Japan: with a medical interview), and agrees to follow the contraceptive guidance from the time of informed consent through at least 5 half-lives (45 days) plus 6 months after final investigational study intervention administration.
  • Female participant must not be breastfeeding or lactating starting at screening and throughout the investigational period and for 5 half-lives (45 days) plus 6 months after final investigational study intervention administration.

  • Female participant must not donate ova starting at first administration of study intervention and throughout the investigational period and for 5 half-lives (45 days) plus 6 months after final investigational study intervention administration.

  • Male participant must agree to use contraception with female partner(s) of childbearing potential (including breastfeeding partner) throughout the treatment period and for 5 half-lives (45 days) plus 3 months after final investigational study intervention administration.

  • Male participant must agree to remain abstinent or use a condom with pregnant partner(s) for the duration of the pregnancy throughout the investigational period and for 5 half-lives (45 days) plus 3 months after final investigational study intervention administration.

  • Male participant must not donate sperm during the treatment period and for 5 half-lives (45 days) plus 3 months after final investigational study intervention administration.

  • Participant must meet all of the criteria based on the locally analyzed laboratory tests collected within 14 days prior to the first dose of study intervention. In case of multiple local laboratory tests within this period, the most recent data should be used.

  • Participant is willing to provide or has sufficient tumor tissue for central biomarker assessment.

  • Participant agrees not to participate in another interventional study while receiving study intervention in the present study.

Exclusion Criteria:

  • Cohorts 1, 2 and 3 only: Participant's disease is of the non-adenocarcinoma histology or mixed histology containing adenocarcinoma.

  • Cohorts 1, 2 and 3 only: Participant has received > 2 prior lines of therapy for uLA/m disease.

    • Participants in Cohort 4 (pan-tumor) may enroll regardless of the number of prior lines of therapy, if they are not eligible for, decline, or do not have any available standard of care treatment options.
  • Participant has complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent recurrent vomiting.

  • Participant has significant gastric bleeding or had a significant bleeding episode from the gastrointestinal tract within 3 months prior to the first dose of study intervention and/or an untreated peptic ulcer disease that would preclude the participant from participation.

  • Participant has significant bleeding disorders or has had vasculitis within 3 months prior to the first dose of study intervention.

  • Participant has a history of gastrointestinal perforation and/or fistula within 6 months prior to the first dose of study intervention.

  • Participant has symptomatic, untreated brain metastases or meningeal carcinomatosis (carcinomatous meningitis) from the primary malignancy. A participant with stable central nervous system metastases for > 3 months without need of steroids for >= 2 weeks prior to the first dose of study intervention is eligible.

  • Participant has a past or current mental illness that is difficult to control.

  • Participant has unresolved pneumonitis or a history of non-infectious pneumonitis such as immune-related pneumonitis or radiation-induced pneumonitis for which the participant is taking glucocorticoids or needed glucocorticoids within 6 months prior to the first dose of study intervention.

  • Participant has a known history of a positive test for human immunodeficiency virus (HIV) infection or known active hepatitis B (positive hepatitis B surface antigen [HBsAg]) or hepatitis C infection. Screening for these infections should be conducted if indicated per local requirements.

    • If participant is negative for HBsAg, but hepatitis B core antibody (HBcAb) and/or hepatitis B surface antibody (HBsAb) positive, a hepatitis B DNA test will be performed; if the test is positive, the participant will be excluded.
    • Participant with positive hepatitis C virus (HCV) serology, but negative HCV RNA test results, is eligible.
    • Participant treated for HCV with undetectable viral load results is eligible.
  • Participant has an active infection requiring systemic therapy that has not completely resolved within 7 days prior to the first dose of study intervention.

  • Participant has a malignancy for which treatment is required, has a history of another malignancy within the past 5 years, except malignancies for which participant received curative therapy without recurrence for the last 5 years (e.g., adequately resected non-melanoma skin cancer, localized prostate cancer), or had treatment for carcinoma in situ.

  • Participant has clinically significant third spacing (large amount of pleural fluid or ascites) that requires frequent percutaneous draining or requires placement of a drainage catheter for adequate control.

  • Participant has any AE from prior antitumor treatments that has not yet recovered to grade 0 or 1 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v6.0 (except alopecia).

  • Participant has an active autoimmune disease or other medical condition that has required high dose systemic steroids at the time of screening.

  • Participant has known peripheral neuropathy > grade 1 (except when the sole neurological abnormality is absence of deep tendon reflexes).

  • Participant has sinusoidal obstruction syndrome, formerly known as veno-occlusive disease; if present, should be stable or improving.

  • Participant has significant cardiovascular disease, including any of the following:

    • Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, cerebrovascular accident or hypertensive crisis within 6 months prior to the first dose of study intervention.
    • History of clinically significant ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes), cardiac arrhythmias requiring anti-arrhythmic medications (a participant with rate controlled atrial fibrillation for > 1 month prior to the first dose of study intervention is eligible) or obligate use of cardiac pacemaker.
    • QTc interval > 470 msec
    • Documented history or family history of congenital long QT syndrome.
  • Participant has ongoing or previous interstitial lung disease, active diverticulitis or solid organ or stem cell transplant.

  • Participant has a serious non-healing wound or bone fracture within 28 days prior to study intervention.

  • Participant has had a major surgical procedure within 28 days prior to the first dose of study intervention and has not completely recovered from the surgical procedure <= 14 days prior to the first dose of study intervention.

  • Participant has received chemotherapy, immunotherapy or investigational therapy <= 14 days prior to the first dose of study intervention and has not recovered from any related toxicity. Palliative radiotherapy is allowed and must be completed > 14 days prior to the first dose of study intervention.

  • Participant has received prior CLDN18.2 ADC. Prior treatment with CLDN18.2 monoclonal antibody or bi-specific T-cell engager is allowed.

  • Participant has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention.

  • Participant has a known or suspected hypersensitivity to ASP546C or any components of the formulation used.

  • Participant has a clinically significant disease or comorbidity that in the opinion of the investigator may adversely affect the safe delivery of treatment within this study or make the participant unsuitable for study participation.

  • Cohorts 1 and 2 (gastroesophageal adenocarcinoma) only: Participant has known HER2 positive status defined as immunohistochemistry (IHC) 3+ or IHC 2+/ in situ hybridization (ISH) +. ISH positive is defined as HER2/ chromosome enumeration probe 17 (CEP17) ratio ≥ 2.0 or an average HER2 copy number ≥ 6.0 signals/cell.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Part 1 - Cohort 1 ASP546C Lower Dose

Participants with unresectable locally advanced or metastatic (uLA/m) gastroesophageal adenocarcinoma will receive a lower dose of ASP546C intravenously, once every 3 weeks (Q3W).

Intravenous administration

Другие имена:
  • XNW27011
Экспериментальный: Part 1 - Cohort 2 ASP546C Higher Dose

Participants with uLA/m gastroesophageal adenocarcinoma will receive a higher dose of ASP546C intravenously, once Q3W.

Intravenous administration

Другие имена:
  • XNW27011
Экспериментальный: Part 2 - Cohort 3 ASP546C Higher Dose

Participants with uLA/m pancreatic adenocarcinoma will receive a higher dose of ASP546C intravenously, once Q3W.

Intravenous administration

Другие имена:
  • XNW27011
Экспериментальный: Part 2 - Cohort 4 ASP546C Higher Dose

Participants with pan-tumor (cholangiocarcinoma, colorectal adenocarcinoma, NSCLC, SCLC, ovarian mucinous carcinoma or invasive breast cancer) will receive a higher dose of ASP546C intravenously, once Q3W.

Intravenous administration

Другие имена:
  • XNW27011

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Part 1: Objective Response Rate (ORR) per Investigator-assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Временное ограничение: Up to 36 Months

ORR is defined as the proportion of participants who have a best overall response (BOR) of complete response (CR) or partial response (PR) as per investigator assessment per RECIST v1.1.

Up to 36 Months
Part 1: Pharmacokinetics (PK) of ASP546C Antibody-drug Conjugate (ADC): Serum Concentrations of Antibody-drug Conjugate
Временное ограничение: Up to 39 Months

ADC concentrations will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1: PK of ASP546C ADC: Maximum Concentration (Cmax)
Временное ограничение: Up to 39 Months

Cmax will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1: PK of ASP546C ADC: Area Under the Serum Concentration-time Curve from Time Zero to 21Days (AUC0-21d)
Временное ограничение: Up to 39 Months

AUC0-21d will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1: Number of participants with Adverse events (AEs)
Временное ограничение: Up to 39 Months

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator, if applicable, and events related to the (study) procedures.

Up to 39 Months
Part 1: Number of Participants with Vital Sign Abnormalities and/or AEs
Временное ограничение: Up to 39 Months

Number of participants with potentially clinically significant vital sign values.

Up to 39 Months
Part 1: Number of Participants with Laboratory Value Abnormalities and/or AEs
Временное ограничение: Up to 39 Months

Number of participants with potentially clinically significant laboratory values.

Up to 39 Months
Part 1: Number of Participants at Each Grade of Eastern Cooperative Oncology Group (ECOG) Performance Status Scores
Временное ограничение: Up to 39 Months

The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance.

Up to 39 Months

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Part 1 and Part 2: ORR per Investigator-assessed per RECIST v1.1
Временное ограничение: Up to 36 Months

ORR is defined as the proportion of participants who have a BOR of CR or PR as per investigator assessment per RECIST v1.1.

Up to 36 Months
Part 1 and Part 2: Disease Control Rate (DCR) per Investigator-assessed per RECIST v1.1
Временное ограничение: Up to 36 Months

DCR defined as the proportion of participants with a BOR of CR, PR or stable disease (SD) as per investigator assessment per RECIST v1.1.

Up to 36 Months
Part 1 and Part 2: Duration of Response (DOR) per Investigator-assessed per RECIST v1.1
Временное ограничение: Up to 36 Months

DOR is defined as the time from the date of the first response (CR/PR) until the date of radiologic disease progression as per investigator assessment per RECIST v1.1 or date of death from any cause, whichever is earlier.

Up to 36 Months
Part 1 and Part 2: Progression Free Survival (PFS) per Investigator-assessed per RECIST v1.1
Временное ограничение: Up to 39 Months

PFS is defined as the time from the date of first dose until the date of radiologic disease progression as per investigator assessment per RECIST v1.1 or death from any cause, whichever is earlier.

Up to 39 Months
Part 1 and Part 2: Overall Survival (OS)
Временное ограничение: Up to 39 Months

OS is defined as the time from the date of first dose until the documented date of death from any cause

Up to 39 Months
Part 2: Number of Participants with AEs
Временное ограничение: Up to 39 Months

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator, if applicable, and events related to the (study) procedures.

Up to 39 Months
Part 2: Number of Participants with Vital Sign Abnormalities and/or AEs
Временное ограничение: Up to 39 Months

Number of participants with potentially clinically significant vital sign values.

Up to 39 Months
Part 2: Number of Participants with Laboratory Value Abnormalities and/or AEs
Временное ограничение: Up to 39 Months

Number of participants with potentially clinically significant laboratory values.

Up to 39 Months
Part 2: Number of Participants at Each Grade of ECOG Performance Status Scores
Временное ограничение: Up to 39 Months

The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance.

Up to 39 Months
Part 1 and Part 2: Change from baseline in Expression Levels of Claudin 18.2 (CLDN18.2)
Временное ограничение: Baseline and up to Day 58

Comparison of CLDN18.2 expression at baseline versus on-treatment tumor biopsies will be performed.

Baseline and up to Day 58
Part 1 and Part 2: PK of ASP546C ADC: Concentration at the End of Infusion (CEOI)
Временное ограничение: Up to 39 Months

CEOI will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Unconjugated Payload: CEOI
Временное ограничение: Up to 39 Months

CEOI will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Total Antibody: CEOI
Временное ограничение: Up to 39 Months

CEOI will be recorded from the PK serum samples collected.

Up to 39 Months
Part 2: PK of ASP546C ADC: AUC0-21d
Временное ограничение: Up to 39 Months

AUC0-21d will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Unconjugated Payload: AUC0-21d
Временное ограничение: Up to 39 Months

AUC0-21d will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Total Antibody: AUC0-21d
Временное ограничение: Up to 39 Months

AUC0-21d will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C ADC: Trough Concentration (Ctrough)
Временное ограничение: Up to 39 Months

Concentration immediately prior to dosing at multiple dosing (Ctrough) will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Unconjugated Payload: Ctrough
Временное ограничение: Up to 39 Months

Concentration immediately prior to dosing at multiple dosing (Ctrough) will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Total Antibody: Ctrough
Временное ограничение: Up to 39 Months

Concentration immediately prior to dosing at multiple dosing (Ctrough) will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C ADC: Time of Maximum Concentration (tmax)
Временное ограничение: Up to 39 Months

tmax will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Unconjugated Payload: tmax
Временное ограничение: Up to 39 Months

tmax will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Total Antibody: tmax
Временное ограничение: Up to 39 Months

tmax will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C ADC: Terminal Elimination Half-life (t1/2)
Временное ограничение: Up to 39 Months

t1/2 will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Unconjugated Payload: t1/2
Временное ограничение: Up to 39 Months

t1/2 will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Total Antibody: t1/2
Временное ограничение: Up to 39 Months

t1/2 will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C ADC: Clearance (CL)
Временное ограничение: Up to 39 Months

CL will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Unconjugated Payload: CL
Временное ограничение: Up to 39 Months

CL will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Total Antibody: CL
Временное ограничение: Up to 39 Months

CL will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C ADC: Volume of Distribution at Steady State (Vss)
Временное ограничение: Up to 39 Months

Vss will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Unconjugated Payload: Vss
Временное ограничение: Up to 39 Months

Vss will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Total Antibody: Vss
Временное ограничение: Up to 39 Months

Vss will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: Number of Participants with all Anti-drug Antibodies (Total Antibody and ADC) Against ASP546C
Временное ограничение: Up to 22 Months

Number of participants with anti-drug antibodies will be reported.

Up to 22 Months

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Следователи

  • Директор по исследованиям: Study Physician, Astellas Pharma Global Development, Inc.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

4 мая 2026 г.

Первичное завершение (Оцененный)

31 июля 2029 г.

Завершение исследования (Оцененный)

31 июля 2029 г.

Даты регистрации исследования

Первый отправленный

18 марта 2026 г.

Впервые представлено, что соответствует критериям контроля качества

18 марта 2026 г.

Первый опубликованный (Действительный)

23 марта 2026 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

13 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

12 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Другие идентификационные номера исследования

  • 546C-CL-0201

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

ДА

Описание плана IPD

Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Сроки обмена IPD

Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Критерии совместного доступа к IPD

Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Совместное использование IPD Поддерживающий тип информации

  • STUDY_PROTOCOL
  • САП
  • КСО

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .